# A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

> **NCT04913220** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 46 (actual)

## Conditions studied

- Malignant Melanoma
- Squamous Cell Carcinoma of Skin

## Interventions

- **DRUG:** THOR-707
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT04913220
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-15
- **Primary completion:** 2023-08-22
- **Final completion:** 2025-02-18
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Early discontinuation based on strategic sponsor decision not driven by any safety concerns
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913220, "A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04913220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*